Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Deals
On this week's podcast, Medtech Insight's Catherine Longworth chats with Marion Webb about some key takeaways from this year's JP Morgan Healthcare Conference. That includes a Q&A with Smith & Nephew's new CEO Namal Nawana on his growth strategy for the British medtech giant, new partnership announcements between medtech and tech companies, and trends in digital health.
Abbott has exercised an option to buy Cephea Valve Technologies, developer of a minimally-invasive replacement heart valve, for an undisclosed sum.
GE Healthcare is collaborating with Vanderbilt University Medical Center to develop AI-powered diagnostic tools for cancer care. Ben Newton, GE Healthcare's chief digital officer, explained that GE hopes the partnership will help GE become a leader in precision medicine by developing algorithms and artificial intelligence systems that can predict adverse events in cancer patients.
Ascensia Diabetes Care plans to start selling its first continuous glucose monitoring devices this year based on a distribution deal with Zhejiang POCTech Co. Ltd, announced Jan. 7 at the JP Morgan Healthcare Conference. The partnership will also include product development.
Neuromodulation firm Nexstim will launch its SmartFocus TMS system for treating major depressive disorder (MDD) in Canada after signing an exclusive agreement with distributor Canada Health Solutions CHS.
Diagnostics firm Veracyte signed a deal to combine clinical study cohorts with Johnson & Johnson to accelerate development of two nasal swab tests for early detection of lung cancer. See how CEO Bonnie Anderson describes the arrangement here.
Johnson & Johnson has entered a strategic collaboration with genomics diagnostics company Veracyte to develop and commercialize tests for detecting lung cancer.
Boston Scientific has acquired the remaining shares of privately held mitral-valve repair device company Millipede for $325m.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.